Stockreport

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data [Yahoo! Finance]

AnaptysBio, Inc.  (ANAB) 
Last anaptysbio, inc. earnings: 3/2 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.anaptysbio.com/investor-relations
PDF in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema “While ANB032 was safe and well tolerated, w [Read more]